We are live on ! Find out more
NTLA icon

Intellia Therapeutics

143 hedge funds and large institutions have $669M invested in Intellia Therapeutics in 2019 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 45 increasing their positions, 31 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 31

44% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 18

14% more capital invested

Capital invested by funds: $589M → $669M (+$80.7M)

5% more funds holding

Funds holding: 136143 (+7)

3.1% more ownership

Funds ownership: 90.23%93.33% (+3.1%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

32% less call options, than puts

Call options by funds: $2.35M | Put options by funds: $3.46M

Holders
143
Holders Change
+7
Holders Change %
+5.15%
% of All Funds
2.82%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
26
Increased
45
Reduced
31
Closed
18
Calls
$2.35M
Puts
$3.46M
Net Calls
-$1.11M
Net Calls Change
-$2.66M
Name Holding Trade Value Shares
Change
Change in
Stake
WM
51
WS Management
Florida
$758K
SCM
52
Shelton Capital Management
Colorado
$751K +$160K +11,500 +29%
JG
53
Jefferies Group
New York
$721K +$684K +49,175 New
PPA
54
Parametric Portfolio Associates
Washington
$714K +$493K +35,418 +267%
Barclays
55
Barclays
United Kingdom
$668K +$362K +25,989 +133%
Rafferty Asset Management
56
Rafferty Asset Management
New York
$667K -$820K -58,958 -56%
New York State Common Retirement Fund
57
New York State Common Retirement Fund
New York
$618K
UBS AM
58
UBS AM
Illinois
$604K -$24.3K -1,749 -4%
CS
59
Credit Suisse
Switzerland
$595K +$215K +15,479 +62%
Renaissance Technologies
60
Renaissance Technologies
New York
$538K +$511K +36,700 New
GCP
61
GSA Capital Partners
United Kingdom
$492K +$467K +33,533 New
Jacobs Levy Equity Management
62
Jacobs Levy Equity Management
New Jersey
$479K +$454K +32,619 New
DCM
63
Dupont Capital Management
Delaware
$471K +$112K +8,050 +34%
Bank of America
64
Bank of America
North Carolina
$437K -$8.27K -594 -2%
AIG
65
American International Group
New York
$355K -$2.83K -203 -0.8%
Manulife (Manufacturers Life Insurance)
66
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$351K -$2.94K -211 -0.9%
Commonwealth Equity Services
67
Commonwealth Equity Services
Massachusetts
$322K -$18.4K -1,323 -6%
Voloridge Investment Management
68
Voloridge Investment Management
Florida
$299K +$284K +20,382 New
PNC Financial Services Group
69
PNC Financial Services Group
Pennsylvania
$294K +$152K +10,950 +121%
M&T Bank
70
M&T Bank
New York
$274K
VOYA Investment Management
71
VOYA Investment Management
Georgia
$272K +$53.9K +3,874 +26%
RJA
72
Raymond James & Associates
Florida
$268K +$254K +18,264 New
PFO
73
Pathstone Family Office
New Jersey
$266K
KJHP
74
K.J. Harrison & Partners
Ontario, Canada
$265K
Invesco
75
Invesco
Georgia
$262K -$16.3K -1,175 -6%

NTLA Hedge Fund Activity: Q4 2019 in Review

143 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2019, worth a combined $669M — up 14% from $589M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new NTLA positions and 18 closed out — a net gain of 8 holders — while 45 added to existing stakes and 31 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $10.6M. The largest seller was Ontario Teachers' Pension Plan Board, exiting entirely with an estimated $10.7M sold.

  • 143 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2019, up from 136 in Q3 2019.
  • Funds reported $669M of Intellia Therapeutics stock for Q4 2019, up 14% quarter-over-quarter.
  • 26 funds opened new Intellia Therapeutics positions in Q4 2019 and 18 closed out, a net change of +8 holders.
  • The largest Intellia Therapeutics buyer in Q4 2019 was Fidelity Investments, an estimated $10.6M added.
  • The largest Intellia Therapeutics seller in Q4 2019 was Ontario Teachers' Pension Plan Board, an estimated $10.7M sold.

Based on aggregated 13F filings for Q4 2019.